Immunome Stock Fundamentals
| IMNM Stock | USD 13.47 1.94 16.83% |
Immunome fundamentals help investors to digest information that contributes to Immunome's financial success or failures. It also enables traders to predict the movement of Immunome Stock. The fundamental analysis module provides a way to measure Immunome's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Immunome stock.
At this time, Immunome's Total Operating Expenses is very stable compared to the past year. As of the 27th of November 2024, Reconciled Depreciation is likely to grow to about 734.2 K, though Operating Income is likely to grow to (104.1 M). Immunome | Select Account or Indicator |
Immunome Company Operating Margin Analysis
Immunome's Operating Margin shows how much operating income a company makes on each dollar of sales. It is one of the profitability indicators which helps analysts to understand whether the firm is successful or not making money from everyday operations.
Current Immunome Operating Margin | (15.06) % |
Most of Immunome's fundamental indicators, such as Operating Margin, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Immunome is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
A good Operating Margin is required for a company to be able to pay for its fixed costs or payout its debt, which implies that the higher the margin, the better. This ratio is most effective in evaluating the earning potential of a company over time when comparing it against a firm's competitors.
| Competition |
Based on the recorded statements, Immunome has an Operating Margin of -15.057%. This is 57.08% lower than that of the Biotechnology sector and 86.56% lower than that of the Health Care industry. The operating margin for all United States stocks is 173.27% higher than that of the company.
Immunome Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Immunome's current stock value. Our valuation model uses many indicators to compare Immunome value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Immunome competition to find correlations between indicators driving Immunome's intrinsic value. More Info.Immunome is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . At this time, Immunome's Return On Equity is very stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Immunome by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Immunome Operating Margin Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Immunome's direct or indirect competition against its Operating Margin to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Immunome could also be used in its relative valuation, which is a method of valuing Immunome by comparing valuation metrics of similar companies.Immunome is currently under evaluation in operating margin category among its peers.
Immunome Current Valuation Drivers
We derive many important indicators used in calculating different scores of Immunome from analyzing Immunome's financial statements. These drivers represent accounts that assess Immunome's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Immunome's important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 77.3M | 97.9M | 149.5M | 26.8M | 212.3M | 222.9M | |
| Enterprise Value | 75.3M | 58.7M | 100.6M | 6.8M | 115.3M | 121.1M |
Immunome ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Immunome's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Immunome's managers, analysts, and investors.Environmental | Governance | Social |
Immunome Fundamentals
| Return On Equity | -2.76 | ||||
| Return On Asset | -0.4 | ||||
| Operating Margin | (15.06) % | ||||
| Current Valuation | 482.26 M | ||||
| Shares Outstanding | 62.42 M | ||||
| Shares Owned By Insiders | 16.77 % | ||||
| Shares Owned By Institutions | 83.47 % | ||||
| Number Of Shares Shorted | 10.67 M | ||||
| Price To Book | 3.35 X | ||||
| Price To Sales | 71.05 X | ||||
| Revenue | 14.02 M | ||||
| EBITDA | (28.27 M) | ||||
| Net Income | (106.81 M) | ||||
| Cash And Equivalents | 34.65 M | ||||
| Cash Per Share | 2.86 X | ||||
| Total Debt | 1.65 M | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 4.36 X | ||||
| Book Value Per Share | 4.97 X | ||||
| Cash Flow From Operations | (7.57 M) | ||||
| Short Ratio | 15.99 X | ||||
| Earnings Per Share | (7.94) X | ||||
| Target Price | 30.0 | ||||
| Number Of Employees | 55 | ||||
| Beta | 1.82 | ||||
| Market Capitalization | 719.67 M | ||||
| Total Asset | 148.54 M | ||||
| Retained Earnings | (222.81 M) | ||||
| Working Capital | 122.87 M | ||||
| Net Asset | 148.54 M |
About Immunome Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Immunome's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Immunome using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Immunome based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | 12.1 M | 12.7 M | |
| Total Revenue | 14 M | 14.7 M | |
| Cost Of Revenue | 22.9 M | 24.1 M | |
| Stock Based Compensation To Revenue | 0.40 | 0.35 | |
| Sales General And Administrative To Revenue | 1.26 | 1.12 | |
| Research And Ddevelopement To Revenue | 6.62 | 5.89 | |
| Capex To Revenue | 0.05 | 0.05 | |
| Revenue Per Share | 0.64 | 0.57 | |
| Ebit Per Revenue | (7.03) | (7.38) |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Immunome Piotroski F Score and Immunome Altman Z Score analysis. To learn how to invest in Immunome Stock, please use our How to Invest in Immunome guide.You can also try the Money Managers module to screen money managers from public funds and ETFs managed around the world.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Immunome. If investors know Immunome will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Immunome listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (7.94) | Revenue Per Share 0.189 | Quarterly Revenue Growth (0.18) | Return On Assets (0.40) | Return On Equity (2.76) |
The market value of Immunome is measured differently than its book value, which is the value of Immunome that is recorded on the company's balance sheet. Investors also form their own opinion of Immunome's value that differs from its market value or its book value, called intrinsic value, which is Immunome's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Immunome's market value can be influenced by many factors that don't directly affect Immunome's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Immunome's value and its price as these two are different measures arrived at by different means. Investors typically determine if Immunome is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Immunome's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.